Dr Nikhil Vergis is Senior Director and a Clinical Development Leader at GSK in Hepatology. He has led clinical trials in SLD for multiple drugs at GSK. He was heavily involved in the initiation of one of the first industry-sponsored trials in Alcohol-related Liver Disease – the STARLIGHT study. Prior to joining GSK, he was a Consultant Hepatologist at Imperial College NHS Trust and concurrently held a post-doctoral Fellowship with Imperial College London and the Wellcome Trust.

Nikhil has over 15 years’ experience in steatohepatitis research at Imperial College London. Areas of focus include immune dysfunction in steatohepatitis and the determinants and impact of alcohol-related hepatitis. Prior to joining industry, he led Phase 2 and Phase 3 university-sponsored clinical trials. 

He continues to see patients with SLD in an integrated clinic at St Mary’s Hospital, London, and holds both Honorary Consultant Hepatologist and Honorary Clinical Senior Lecturer positions with Imperial College NHS Trust and Imperial College London, respectively.